Margin of Safety Dashboard

Recursion Pharmaceuticals

RXRX

$
2.94
(
-6.7
%)
(
+
-6.7
%)
+
-24.8
%
2.21
NASDAQ

Last Price

03/27/26, 09:30 AM
 EDT

Margin of Safety

Future Compounder
$
2.21

PORTFOLIO CATEGORY

Modeled fair value

Up to 2.5%
$1.032 billion

Allocation Suggestion

Modeled fair value

Model Basis

LAST REFINED:
May 5, 2025
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • REC-617 in advanced solid tumors driven by CDK7 (phase 1/2)
  • REC-4881 in familial adenomatous polyposis (phase 1/2)
The current model EXCLUDES the following assets:
  • REC-1245 in solid tumors (phase 1)
  • REC-3565 in B-cell malignancies (phase 1)
  • REC-4539 in small-cell lung cancer (SCLC) (phase 1)
  • REC-7735 in PI3K-alpha kinase mutant HR+/HER2- breast cancer (preclinical)
  • REC-102 in hypophosphatasia (preclinical)

SEC Filings

Show More
Back to Top
ABOUT
What Is Solt DB?
Public Benefit
Our Lonely Team
PUBLIC CONTENT
Articles
Data Visualizations
Newsletter
INVESTING
Pricing
Member Benefits
Stocks We Cover
CONTACT
Questions?
Critiques?
Love letters?

Reach out here.
About Solt DB

Solt DB is an equities research firm and public benefit company exploring the business of biotech. For scientists, investors, and nerds of all stripes – or feathers.

Yinz respect the finch n@. 2026 Solt DB.
A white logo of LinkedIn.